ABIO ARCA biopharma Inc.
NewsSee all news
-
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER,
-
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for
-
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for
Drug Information
Drug catalyst information is displayed when you hover over / tap on the stage bar graph.
Latest News
-
ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update
PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER,
-
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for
-
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for